Our Diversity, Equity, and Inclusion (DEI) Purpose At Ionis, we encourage diversity in our workforce. Prejudicial barriers to human potential and productivity are foreign to our values. We recognize that in order for the full potential of our workforce to be realized, we must cultivate an inclusive culture where all employees feel empowered to contribute […]
Overview As a part of our commitment to discover, develop, and deliver medicines to the patients who depend on us, we believe in supporting investigator-initiated research (IIR) to advance medical and scientific knowledge in our research areas of interest. We define IIR as unsolicited research conceived, initiated, and conducted independently of Ionis. An external investigator […]
Mr. Klein has served as a director of Ionis since December 2005. Mr. Klein is currently managing director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008, Mr. Klein also served as a venture partner of Red […]
Dr. Michael Hayden is a Killam Professor at the University of British Columbia and the director of the Translational Laboratory in Genetic Medicine at the National University of Singapore and the Agency for Science, Technology and Research (A*STAR). From 2012 to 2017, he served as president of Global R&D and chief scientific officer at Teva […]